Aquestive Therapeutics AQST 深 滬
已收盤 02-06 16:00:00 美东时间
4.11
+0.270
+7.03%
華盛通- 最 高4.18
- 今 開3.91
- 成交量 293.95万股
- 最 低 3.875
- 昨 收 3.84
- 總市值 5.01亿
- 52周最高 7.55
- 市盈率 靜 --
- 換手率 2.41%
- 52周最低 2.12
- 委 比 -80.93%
- 總股本 1.22亿
- 歷史最高 20.696
- 量 比 0.18
- 振 幅 7.94%
- 歷史最低 0.618
- 每 手 1
- 風險率 1.43%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | 存储再度狂飙！Sandisk大涨逾15%；生物技术公司TWST涨约14%，Q1业绩超预期
存储再度狂飙！Sandisk大涨逾15%，伯恩斯坦上调目标价至1000美元；生物技术公司TWST涨约14%，Q1业绩超预期；欧朋涨超13%，此前上调Q4收入预期指引>>
02-03 15:29
Analysts’ Top Healthcare Picks: Aquestive Therapeutics (AQST), Skye Bioscience (SKYE)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
02-03 03:10
Aquestive Therapeutics Receives CRL From FDA For NDA Seeking Approval Of Anaphylm Sublingual Film For Treatment Of Type I Allergic Reactions, Including Anaphylaxis, In Patients Weighing 30kg Or More
Deficiencies limited to packaging and administration Company believes it can rapidly resolve deficiencies and expects to resubmit as early as Q3 2026 Remains well-capitalized and anticipates ending 2026
02-02 20:04
Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™
Aquestive Therapeutics received a Complete Response Letter (CRL) from the FDA regarding its Anaphylm NDA, citing deficiencies in human factors validation and packaging. The company plans to address these issues, conduct new studies, and resubmit the NDA as early as Q3 2026. Anaphylm remains well-supported by clinical data, and the company is optimistic about its potential as a non-invasive epinephrine treatment. The company also intends to submit...
02-02 12:00
Benzinga Bulls And Bears: Chevron, Palantir, Aquestive — And Real Estate Stocks Plummet
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
01-10 21:31
Bad News For Competitor Turns Into Big Win For ARS Pharma Stock
ARS Pharmaceuticals Inc. stock rose Friday as FDA identified deficiencies in rival Aquestive's application, delaying potential competition.
01-10 01:32
Aquestive Stock Slides After FDA Flags Issues With Allergy Drug Application
Aquestive Therapeutics shares fall after the FDA flags deficiencies in its Anaphylm allergy drug application, raising approval delay concerns despite the review remaining active.
01-10 00:28
Aquestive Faces FDA Deficiencies on Anaphylm NDA Review
Aquestive Therapeutics ( ($AQST) ) just unveiled an update. On January 9, 2026,...
01-09 20:48
Aquestive drops as FDA flags issues in Anaphylm marketing application
Aquestive Therapeutics (AQST) lost ~48% in the premarket on Friday after the company said that the U.S. FDA has identified deficiencies in its new drug application for its allergy therapy, Anaphylm, w...
01-09 20:43
